

Yoshihisa Matsukawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1352166/publications.pdf>

Version: 2024-02-01

48
papers

574
citations

686830

13
h-index

713013

21
g-index

48
all docs

48
docs citations

48
times ranked

655
citing authors

#	ARTICLE	IF	CITATIONS
1	The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. <i>Modern Pathology</i> , 2016, 29, 166-173.	2.9	59
2	Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study. <i>Journal of Urology</i> , 2009, 182, 2831-2835.	0.2	38
3	De novo detrusor underactivity after laparoscopic radical prostatectomy. <i>International Journal of Urology</i> , 2010, 17, 643-648.	0.5	37
4	Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder. <i>Urology</i> , 2015, 85, 786-790.	0.5	30
5	De novo overactive bladder after robot-assisted laparoscopic radical prostatectomy. <i>Neurourology and Urodynamics</i> , 2018, 37, 2008-2014.	0.8	27
6	Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study. <i>International Journal of Urology</i> , 2018, 25, 246-250.	0.5	23
7	Clinical characteristics and useful signs to differentiate detrusor underactivity from bladder outlet obstruction in men with non-neurogenic lower urinary tract symptoms. <i>International Journal of Urology</i> , 2020, 27, 47-52.	0.5	23
8	Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study. <i>Journal of Urology</i> , 2013, 189, S117-21.	0.2	20
9	Long-term efficacy of a combination therapy with an anticholinergic agent and an α -blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study. <i>Neurourology and Urodynamics</i> , 2017, 36, 748-754.	0.8	18
10	Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: The 1-year outcomes from a prospective urodynamic study. <i>International Journal of Urology</i> , 2014, 21, 826-830.	0.5	17
11	Laparoscopic versus open radical prostatectomy: Urodynamic evaluation of vesicourethral function. <i>International Journal of Urology</i> , 2009, 16, 393-396.	0.5	16
12	Effects of Withdrawing α -Blocker from Combination Therapy with α -Blocker and 5 α -Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics. <i>Journal of Urology</i> , 2017, 198, 905-912.	0.2	15
13	Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies. <i>Neurourology and Urodynamics</i> , 2019, 38, 941-949.	0.8	15
14	Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia. <i>World Journal of Urology</i> , 2011, 29, 225-231.	1.2	14
15	Effect of Tamsulosin on Bladder Microcirculation in Rat Model of Bladder Outlet Obstruction Using Pencil Lens Charge-coupled Device Microscopy System. <i>Urology</i> , 2013, 81, 155-159.	0.5	14
16	Effect of Naftopidil on Bladder Microcirculation in a Rat Model of Bladder Outlet Obstruction. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017, 9, 111-116.	0.6	14
17	Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study). <i>Journal of Urology</i> , 2017, 197, 452-458.	0.2	14
18	Role of microglia in the spinal cord in colon-to-bladder neural crosstalk in a rat model of colitis. <i>Neurourology and Urodynamics</i> , 2018, 37, 1320-1328.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Clinical diagnostic criteria for detrusor underactivity: A report from the Japanese Continence Society working group on underactive bladder. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 13-16.	0.6	14
20	Effect of Tamsulosin on Bladder Microcirculation in a Rat Ischemia-reperfusion Model, Evaluated by Pencil Lens Charge-coupled Device Microscopy System. Urology, 2010, 76, 1266.e1-1266.e5.	0.5	13
21	What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? investigation using a pressure-flow study. Neurourology and Urodynamics, 2013, 32, 266-270.	0.8	13
22	Variability of post-void residual urine volume and bladder voiding efficiency in patients with underactive bladder. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 51-55.	0.6	13
23	Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study. World Journal of Urology, 2019, 37, 867-872.	1.2	12
24	Causative factors for de novo inguinal hernia after robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2018, 12, 277-282.	1.0	11
25	Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms. International Journal of Urology, 2017, 24, 454-459.	0.5	10
26	What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study. Neurourology and Urodynamics, 2017, 36, 1809-1815.	0.8	7
27	Investigation of the relationship between bladder function and sarcopenia using pressure flow studies in elderly male patients. Neurourology and Urodynamics, 2019, 38, 1417-1422.	0.8	7
28	A small pilot study to evaluate the accuracy and feasibility of a novel automated voiding diary device for recording urine output measurements. Neurourology and Urodynamics, 2021, 40, 272-277.	0.8	7
29	Feasibility of the Liliu $\hat{\pm}$ 200 portable ultrasound bladder scanner for accurate bladder volume measurement. Investigative and Clinical Urology, 2020, 61, 613.	1.0	7
30	A Slow Stream Is Pathophysiologically Related to a Poor Response to $\hat{\pm}$ 1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia. Urology, 2015, 86, 558-564.	0.5	6
31	Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. Neurourology and Urodynamics, 2020, 39, 1994-2002.	0.8	6
32	Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics. Therapeutic Advances in Urology, 2018, 10, 263-272.	0.9	5
33	Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction. Aging Male, 2020, 23, 641-647.	0.9	4
34	Effects of tadalafil versus silodosin on voiding function in male patients with non-neurogenic detrusor underactivity: A comparative study using propensity score matching. International Journal of Urology, 2021, 28, 411-416.	0.5	4
35	Effect of chemotherapy on survival for intraductal carcinoma of the prostate (IDC-P) in patients with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, e601-e601.	0.8	4
36	Associations among Physician-Patient Communication, Patient Satisfaction, and Clinical Effectiveness of Overactive Bladder Medication: A Survey of Patients with Overactive Bladder. Journal of Clinical Medicine, 2022, 11, 4087.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Urodynamic evaluation before and after to RARP to identify pre and intraoperative factors affecting postoperative continence. <i>Neurourology and Urodynamics</i> , 2021, 40, 1147-1153.	0.8	3
38	Development of an artificial intelligence diagnostic system for lower urinary tract dysfunction in men. <i>International Journal of Urology</i> , 2021, 28, 1143-1148.	0.5	3
39	The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia. <i>Urology</i> , 2016, 88, 149-154.	0.5	2
40	What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?. <i>Urologia Internationalis</i> , 2019, 103, 439-443.	0.6	2
41	Factors contributing to the efficacy of two additional therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms. <i>International Journal of Urology</i> , 2020, 27, 85-86.	0.5	2
42	Useful parameters to predict the presence of detrusor overactivity in male patients with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020, 39, 1394-1400.	0.8	2
43	Daily urine loss immediately after urethral catheter removal may be an effective predictor of long-term urinary incontinence following robot-assisted laparoscopic radical prostatectomy. <i>International Journal of Clinical Practice</i> , 2021, 75, e13736.	0.8	2
44	Validation and clinical utility of the diagnostic criteria for detrusor underactivity in men proposed by the Japanese Continence Society. <i>International Journal of Urology</i> , 2022, 29, 595-596.	0.5	2
45	Clinical features and urodynamic findings in elderly men with chronic prostatitis. <i>International Journal of Urology</i> , 2022, , .	0.5	1
46	Reply. <i>Urology</i> , 2015, 86, 563-564.	0.5	0
47	The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study. <i>Prostate</i> , 2020, 80, 1373-1380.	1.2	0
48	Retrospective analysis of post-TKI everolimus therapy for metastatic renal cell carcinoma using the doubling-time of tumor growth.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15574-e15574.	0.8	0